AI Article Synopsis
- Current treatments for vein incompetence often involve either immediate or delayed ablation methods, but this study explores whether a specific procedure called single ambulatory phlebectomy (SAP) is as effective and cost-efficient as thermal endovenous ablation with phlebectomy (TAP).
- A clinical trial involving 464 patients showed that, after one year, those who underwent SAP reported similar quality of life and symptom relief as those who received TAP, with 25.6% of SAP patients needing additional treatment.
- SAP was found to be a cheaper option compared to TAP while providing non-inferior results in patient outcomes, making it a viable alternative in treating vein incompetence.
Article Abstract
Background: Current treatment of patients with saphenous trunk and tributary incompetence consists of truncal ablation with concomitant, delayed or no treatment of the tributary. However, reflux of the saphenous trunk may be reversible after treatment of the incompetent tributary. The aim of this study was to determine whether single ambulatory phlebectomy with or without delayed endovenous truncal ablation (SAP) is non-inferior to thermal endovenous ablation with concomitant phlebectomy (TAP), and whether SAP is a cost-effective alternative to TAP.
Methods: A multicentre, non-inferiority RCT was conducted in patients with an incompetent great saphenous vein or anterior accessory saphenous vein with one or more incompetent tributaries. Participants were randomized to receive SAP or TAP. After 9 months, additional truncal treatment was considered for SAP patients with remaining symptoms. The primary outcome was VEnous INsufficiency Epidemiological and Economic Study Quality of Life/Symptoms (VEINES-QOL/Sym score) after 12 months. Secondary outcomes were, among others, cost-effectiveness, perceived improvement of symptoms, and anatomical success.
Results: Some 464 patients received the allocated treatment (SAP 227, TAP 237). VEINES-QOL scores were 52.7 (95 per cent c.i. 51.9 to 53.9) for SAP and 53.8 (53.3 to 55.1) for TAP; VEINES-Sym scores were 53.5 (52.6 to 54.4) and 54.2 (54.0 to 55.6) respectively. Fifty-eight patients (25.6 per cent) in the SAP group received additional truncal ablation. Treatment with SAP was less costly than treatment with TAP.
Conclusion: One year after treatment, participants who underwent SAP had non-inferior health-related quality of life compared with those who had TAP. Treatment with SAP was a cost-effective alternative to TAP at 12 months.
Registration Number: NTR 4821 (www.trialregister.nl).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364515 | PMC |
| http://dx.doi.org/10.1093/bjs/znac388 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concomitant Pulmonary Vein Isolation for induced Atrial fibrillation to reduce future risk of atrial fibrillation following Ablation for Isolated Atrial Flutter.
Heart Rhythm
January 2025
Department of Cardiology, The affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China.
Background: A significant proportion of patients with isolated atrial flutter (AFL) will develop atrial fibrillation (AF) following cavotricuspid isthmus (CTI) ablation.
Objective: To determine whether concomitant pulmonary vein isolation (PVI) could reduce the incidence of new-onset atrial fibrillation (NOAF) in the setting of inducible AF following CTI ablation.
Methods: A total of 275 consecutive patients with isolated AFL who successfully underwent CTI ablation were included.
Current Real-World Status of Off-Label Under- and Over-Dose of Direct Oral Anticoagulants After Atrial Fibrillation Ablation.
J Cardiovasc Electrophysiol
January 2025
Department of Cardiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Background: Off-label under- and overdosing of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) is not uncommon in real-world practice.
Objective: This study aimed to identify efficacy and safety of off-label DOACs dose after AF ablation.
Methods: The RYOUMA registry was a prospective multicenter study of Japanese patients who underwent AF ablation between 2017 and 2018.
Rhythm Control Better Prevents Stroke than Rate Control in Patients with Concomitant Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Nationwide Population Based Cohort Study with Long-Term Follow-Up.
Acta Cardiol Sin
January 2025
Cardiovascular Center, Taichung Veterans General Hospital, Taichung.
Background: Atrial fibrillation (AF) increases the risks of stroke and mortality. It remains unclear whether rhythm control reduces the risk of stroke in patients with AF concomitant with hypertrophic cardiomyopathy (HCM).
Methods: We identified AF patients with HCM who were ≥ 18 years old in the Taiwan National Health Insurance Database.
The cGAS-STING, p38 MAPK, and p53 pathways link genome instability to accelerated cellular senescence in ATM-deficient murine lung fibroblasts.
Proc Natl Acad Sci U S A
January 2025
Department of Human Molecular Genetics and Biochemistry, Faculty of Health & Medical Sciences, Tel Aviv University, Tel Aviv 69978, Israel.
Ataxia-telangiectasia (A-T) is a pleiotropic genome instability syndrome resulting from the loss of the homeostatic protein kinase ATM. The complex phenotype of A-T includes progressive cerebellar degeneration, immunodeficiency, gonadal atrophy, interstitial lung disease, cancer predisposition, endocrine abnormalities, chromosomal instability, radiosensitivity, and segmental premature aging. Cultured skin fibroblasts from A-T patients exhibit premature senescence, highlighting the association between genome instability, cellular senescence, and aging.
View Article and Find Full Text PDFAvailability of the Great Saphenous Veins as Conduits for Arterial Bypass Surgery in Patients with Varicose Veins.
J Clin Med
December 2024
Department of Fundamental and Applied Research in Vascular Surgery, Pirogov Russian National Research Medical University, 119049 Moscow, Russia.
The great saphenous vein (GSV) has long been recognized as the best conduit for vascular bypass procedures. Concomitant varicose veins disease may be a reason for GSV unavailability either due to dilatation and tortuosity of the vein or due to its destruction during invasive venous treatment. -to assess the rate of varicose vein patients with concomitant lower extremity arterial disease (LEAD) who have previously lost their GSV due to venous ablation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!